Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02734290
Recruitment Status : Recruiting
First Posted : April 12, 2016
Last Update Posted : October 29, 2018
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Providence Health & Services

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : May 2021
  Estimated Study Completion Date : May 2022